James Doherty

Sage Therapeutics (United States) — United States

Neuroscience · Life Sciences

32h-index4.9kcitations91works10.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(50), Receptor Mechanisms and Signaling(22), Tryptophan and brain disorders(13), Memory and Neural Mechanisms(6), Maternal Mental Health During Pregnancy and Postpartum(6)

Publications91 total

Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease
Clinical and Translational Science·2024· 10 citedOpen Access
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder
The Journal of Clinical Psychiatry·2023· 13 citedOpen Access
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
Neuropsychopharmacology·2023· 22 citedOpen Access
Pharmacological characterization of SAGE‐718, a novel positive allosteric modulator of N‐methyl‐<scp>d</scp>‐aspartate receptors
British Journal of Pharmacology·2023· 13 citedOpen Access
Zuranolone for the Treatment of Postpartum Depression
American Journal of Psychiatry·2023· 154 cited
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
American Journal of Psychiatry·2023· 73 cited
The Phase 2, Randomized, Placebo-controlled PRECEDENT Trial of SAGE-718 in Patients With Parkinson's Disease Cognitive Impairment: Clinical Trial in Progress (P2-11.005)
Neurology·2023
Zuranolone, a Positive Allosteric Modulator of the GABA<sub>A</sub> Receptor: Hypothesized Mechanism of Action in Major Depressive Disorder
CNS Spectrums·2023· 6 citedOpen Access
Novel neuroactive steroids as positive allosteric modulators of NMDA receptors: mechanism, site of action, and rescue pharmacology on GRIN variants associated with neurological conditions
Cellular and Molecular Life Sciences·2023· 14 citedOpen Access
J12 The perspective program: evaluating the effect of SAGE-718 on cognitive function in patients with Huntington’s disease
2022
SAGE-718: A First-in-Class<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment
Journal of Medicinal Chemistry·2022· 39 citedOpen Access
SAGE-718 in Parkinson’s Disease Mild Cognitive Impairment: Results from the Phase 2 PARADIGM Study (Part A) (P10-11.004)
Neurology·2022
Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder
Journal of Affective Disorders·2022· 22 citedOpen Access
Preventing Phosphorylation of the GABAAR β3 Subunit Compromises the Behavioral Effects of Neuroactive Steroids
Frontiers in Molecular Neuroscience·2022· 11 citedOpen Access
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
Human Psychopharmacology Clinical and Experimental·2021· 18 citedOpen Access
Effect of Zuranolone vs Placebo in Postpartum Depression
JAMA Psychiatry·2021· 236 citedOpen Access
Oxysterols Modulate the Acute Effects of Ethanol on Hippocampal N-Methyl-D-Aspartate Receptors, Long-Term Potentiation, and Learning
Journal of Pharmacology and Experimental Therapeutics·2021· 9 citedOpen Access
Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study
Journal of the Neurological Sciences·2020· 27 citedOpen Access
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator
Neuropharmacology·2020· 121 citedOpen Access
25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner
Journal of Neuroinflammation·2020· 114 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Stephen Kanes(11), Michael C. Quirk(10), Michael A. Ackley(10), Ethan Hoffmann(9), Albert J. Robichaud(9), Steven M. Paul(8), Raymond Dingledine(8), Jeffrey M. Jonas(6), Robert Lasser(6), Francesco G. Salituro(6), Michael Lewis(6), Shane Raines(5), Rebecca Hammond(5), Charles F. Zorumski(5), Edward P. Christian(5), Abdul J. Sankoh(5), Christopher Silber(5), Amy Bullock(5), Jing Dai(5), Helen Colquhoun(4)